Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
